![EyePoint Pharmaceuticals Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/eypt.png?tr=w-200)
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
![EyePoint Pharmaceuticals Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/eypt.png)
EyePoint Pharmaceuticals Inc
Intangible Assets
EyePoint Pharmaceuticals Inc
Intangible Assets Peer Comparison
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/jnj.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/bmy.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/pfe.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/mrk.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/lly.png)
Competitive Intangible Assets Analysis
Latest Figures & CAGR of Competitors
Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
![]() |
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
![]() |
Johnson & Johnson
NYSE:JNJ
|
Intangible Assets
$34.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
2%
|
![]() |
Bristol-Myers Squibb Co
NYSE:BMY
|
Intangible Assets
$32.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
100%
|
CAGR 10-Years
31%
|
![]() |
Pfizer Inc
NYSE:PFE
|
Intangible Assets
$62.8B
|
CAGR 3-Years
31%
|
CAGR 5-Years
13%
|
CAGR 10-Years
5%
|
![]() |
Merck & Co Inc
NYSE:MRK
|
Intangible Assets
$17.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-2%
|
![]() |
Eli Lilly and Co
NYSE:LLY
|
Intangible Assets
$6.8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|